WHO SHE IS

• A pioneer of Indian biotechnology. The woman who built India’s first globally respected biopharma company—Biocon—and, in doing so, helped put India on the world map for affordable, high-quality biologics.

• She started Biocon in 1978, at age 25, with her savings of Rs 10,000, in a rented garage in Bangalore—when “biotech” wasn’t a word in India, venture capital didn’t exist, and women founders were an anomaly.

• Mazumdar-Shaw’s central thesis: life-saving medicine should not be a luxury available to a few, but affordable and accessible to all who need it. Under her stewardship, Biocon became one of the world’s largest producers of insulin and a major global player in biosimilars—complex, biologic drugs that slash the cost of treatment for cancer, diabetes, and autoimmune diseases.

• Quick tidbit: Banks initially refused her loans because she was a woman, unmarried, and working in an industry no one understood. Suppliers doubted her. Scientists hesitated to join her. Regulators were unconvinced. She built the company anyway.

THE DISRUPTOR 

• Here’s the problem Shaw has taken on: modern medicine works, but it’s priced for the rich world. Biologic drugs routinely cost $50,000–$150,000 per patient per year in the West. Diabetes and cancer—once “diseases of affluence”—are now exploding across low- and middle-income countries. Innovation has outpaced access.
• What the old pharma model says: High prices are inevitable. R&D is expensive. Innovation must be protected at all costs.
• What Mazumdar-Shaw argues: Innovation without access is failure. The next frontier isn’t new molecules alone, it’s democratizing existing breakthroughs at global scale. Her wager: biosimilars. They are hard to make, harder to regulate, but they are capable of collapsing prices by 60–90% without compromising safety or efficacy.

THE BUILDER 

• She’s built India’s first industrial-scale biotech company.

• A vertically integrated biopharma group spanning: biologics & biosimilars, small molecules, novel biologics & immuno-oncology, contract research & manufacturing. 

Key milestones:

• One of the largest insulin producers globally.

• A leading company offering affordable biologics for diabetes. Cancer. Auto-immune conditions. With 10 biosimilar products commercialised in the world markets.

• Impacting over 20 million lives globally. 

• Strategic partnerships with global pharma majors.

• Took Biocon public in 2004—India’s first biotech IPO.

IN HER OWN WORDS

• “Healthcare innovation must reach the last patient, not just the last patent.”

• “Affordability is not the enemy of innovation—it is its purpose.”

• “India’s opportunity is not to copy Big Pharma, but to reinvent it.”

She’s been blunt about excess profiteering, weak public health systems, and the moral failure of allowing treatable diseases to bankrupt families. And that healthcare is infrastructure, not charity.

THE PHILANTHROPIST

• Kiran Mazumdar-Shaw is also the founder of Biocon Foundation—one of India’s most influential health and social impact organizations. Their focus areas: public health & cancer care. Primary healthcare in rural India. Education, nutrition, sanitation. 
• She's the second Indian and first woman business leader to sign the Giving Pledge. A commitment to give away 75% of her wealth for social good. 

AT SYNAPSE 

Kiran Mazumdar-Shaw will speak about biology as the new frontier. Unprecedented pathways towards personalised and preventative drugs. The rise of precision medicine. The revolution in genetics, genomics, and gene-editing technologies. How to expand affordable access—the real moonshot. What will it take to build the right ecosystem. And India's role in redefining global medicine. 

Previous Next